Company intelligence / Profile preview

Escala Capital

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Escala Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel treatments for rare, life-threatening kidney diseases. The company's lead program was sparsentan (formerly ESCA-001), a dual-acting endothelin receptor antagonist and angiotensin receptor blocker. Sparsentan was specifically developed to treat focal segmental glomerulosclerosis (FSGS), a rare condition that often leads to end-stage renal disease. Escala was formed as a subsidiary of Retrophin (now Travere Therapeutics) to advance this specific asset through clinical development.

Therapeutic areas: Nephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

Ligand Pharmaceuticals

Beyond the preview

Go deeper on Escala Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escala Capital.

Explore the full profile